LGND Earnings Date: Feb 25, 2027 (Estimated) — Ligand Pharmaceuticals Incorporated
NASDAQ · Healthcare · Biotechnology
Updated
When is LGND's next earnings date?
Ligand Pharmaceuticals Incorporated (LGND) is expected to report Q4 2026 earnings on Thursday, February 25, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.84 on revenue of $96.8M.
How did LGND do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Ligand Pharmaceuticals Incorporated posted EPS of $2.67 versus the $2.33 estimate, a beat of 14.6%. Revenue was $78.7M against a $77.0M estimate. The stock's 1-day post-earnings move was -0.5%.
How much does LGND stock move after earnings?
LGND beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.6% (up or down) in the day after earnings.
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
🤖 AI Earnings Analysis
Ligand’s royalty engine is strengthening: Q3 royalties rose 51% to $70.3M, and management raised 2026 adjusted EPS guidance to $9.50–$9.75. Despite lower reported revenue and EPS year over year, the outlook and royalty growth are compelling.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 2.33 | 2.67 | +14.59% | $78.7M | ✅ Beat | -0.45% | — | — |
| 2026-08-06 | Q2 2026 | 2.01 | 2.37 | +28.80% | $63.7M | ✅ Beat | -0.80% | -3.07% | -4.24% |
| 2026-05-07 | Q1 2026 | 1.64 | 1.63 | -0.61% | $51.7M | ❌ Miss | -9.55% | -4.88% | +1.91% |
| 2026-02-26 | Q4 2025 | 1.15 | 2.02 | +75.65% | $59.7M | ✅ Beat | +2.50% | +9.18% | +6.43% |
| 2025-11-06 | Q3 2025 | 1.57 | 3.09 | +96.82% | $115.5M | ✅ Beat | +9.37% | +8.00% | -2.89% |
| 2025-08-07 | Q2 2025 | 0.94 | 1.60 | +70.21% | $47.6M | ✅ Beat | +2.75% | +9.55% | +17.15% |
| 2025-02-27 | Q4 2024 | 1.19 | 1.27 | +6.72% | $42.8M | ✅ Beat | +0.57% | +0.35% | -4.62% |
| 2024-11-07 | Q3 2024 | 1.35 | 1.84 | +36.30% | $51.8M | ✅ Beat | +11.12% | +4.43% | +6.78% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $118.4M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Royalty | 40.6% | $48.0M | +32.0% | $31.7M | $77.1M | $27.5M | $36.4M |
| Intangible Royalty Assets | 31.5% | $37.4M | +24.2% | $26.6M | $68.8M | $21.6M | $30.1M |
| Financial Royalty Assets | 9.0% | $10.7M | +69.0% | $5.2M | $8.3M | $5.9M | $6.3M |
| Material Sales, Captisol | 6.7% | $8.0M | -3.7% | $6.3M | $24.6M | $13.5M | $8.3M |
| Kyprolis | 5.9% | $7.0M | -20.0% | $11.6M | — | $4.7M | $8.8M |
| Rylaze | 2.7% | $3.2M | +11.8% | $3.9M | — | $3.1M | $2.9M |
| Contract Revenue | 2.3% | $2.7M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.